Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dysport for prevention of chronic migraine in adults
2023-504827-17-00Phase 3Completed
- Sponsor
- Ipsen
- Start
- Mar 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial in chronic migraine comparing Dysport with Placebo (2 arms). Primary endpoint: Change from baseline at Week 24 in monthly migraine days. Started Mar 2024; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
chronic migraine
Beyond the preview
Go deeper on 2023-504827-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504827-17-00.